The prioritisation board, made up of senior members of NICE, drives our decision-making and maintains oversight of our guidance portfolio. It ensures the topics we select reflect national priorities ...

NICE is unable to make a recommendation on sarilumab (Kevzara) for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years. This is because the company did not ...

NICE is unable to make a recommendation on clascoterone (Winlevi) for treating acne vulgaris in people 12 years and over. This is because the company did not provide an evidence submission.

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...